.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Motor fluctuations are a major challenge in Parkinson disease once levodopa response becomes inconsistent. A randomized clinical trial evaluated safinamide as an add-on treatment in patients already experiencing motor fluctuations while receiving levodopa. The study found that safinamide increased daily “on” time without troublesome dyskinesia compared with placebo and reduced wearing-off. Dyskinesia was more frequent with active treatment, but the overall evidence supported the drug as an adjunctive option for patients whose levodopa response has become less predictable. The practical value of this study lies in its patient-centred endpoint: increasing good “on” time rather than simply changing a laboratory measure or rating-scale subcomponent. For HCPs, treatment should therefore be framed around how the patient experiences fluctuations across the day—mobility, activities, medication timing and troublesome dyskinesia. Safinamide is one of several adjunctive options, so selection should consider contraindications, concomitant medication, adverse effects and patient goals. The trial illustrates the broader movement-disorder principle of adjusting therapy around daily function rather than focusing only on the total dose of levodopa.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Motor fluctuations are a major challenge in Parkinson disease once levodopa response becomes inconsistent. A randomized clinical trial evaluated safinamide as an add-on treatment in patients already experiencing motor fluctuations while receiving levodopa. The study found that safinamide increased daily “on” time without troublesome dyskinesia compared with placebo and reduced wearing-off. Dyskinesia was more frequent with active treatment, but the overall evidence supported the drug as an adjunctive option for patients whose levodopa response has become less predictable. The practical value of this study lies in its patient-centred endpoint: increasing good “on” time rather than simply changing a laboratory measure or rating-scale subcomponent. For HCPs, treatment should therefore be framed around how the patient experiences fluctuations across the day—mobility, activities, medication timing and troublesome dyskinesia. Safinamide is one of several adjunctive options, so selection should consider contraindications, concomitant medication, adverse effects and patient goals. The trial illustrates the broader movement-disorder principle of adjusting therapy around daily function rather than focusing only on the total dose of levodopa.
last month
Preclinical findings demonstrate that ginsenoside Ra1 preserves vascular integrity and attenuates multi-organ injury during sepsis by targeting non-muscle myosin heavy chain IIA (NMMHC IIA) and dampening TLR4/NF-κB/NLRP3 inflammatory signaling.
2 days back
An all-printed immunosensing microchip detects urinary sFlt-1 in just 10 minutes with 3.61 pg/mL sensitivity. By leveraging photonic bandgap engineering, this low-cost, cleanroom-free platform provides non-invasive preeclampsia screening, offering substantial benefits for point-of-care obstetric triage.
3 days back
Wearable ultrasound patches are transforming healthcare by shifting medicine from episodic evaluations to continuous monitoring. Discover how flexible acoustic transducers advance cardiovascular tracking, musculoskeletal imaging, neuromodulation, and on-demand closed-loop theranostics.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
Last week
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
Last week
